Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL therapy plus nivolumab and low-dose interferon-alpha in metastatic melanoma
NL-OMON44437Phase 2Withdrawn
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2017
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab, interferon alfa and GC101 TIL + pembrolizumab in melanoma and cutaneous malignancy, sponsored by Leiden University Medical Center. Primary endpoints: Safety and toxicity and Acceptable toxicity rate. Planned start Oct 2017; status: withdrawn.
02
Drugs
03
Conditions
melanomacutaneous malignancy
Beyond the preview
Go deeper on NL-OMON44437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44437.